Sugar Editorial Picks
Mar 24, 2008 -
Many people live through childhood sleeping with their pet kitties on their pillows, rolling around on dust filled carpets, and collecting flowers and weeds to give to their moms. They do this without a sneeze or sniffle. Those same carefree kids grow up and when they hit their 20s, they suddenly develop allergies to all those things.
- 23 Comments
Other Search Results
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Symptoms
- Causes
- Prognosis
- Risk Factors
- Diagnosis
- Treatment
- Quick-Relief Medications...
- Long-Term Relief Medication...
- Other Treatments
- Managing Asthma
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Warning
In 2007, the FDA requested the manufacturers of omalizumab (Xolair) to include a “boxed warning” emphasizing that this drug may cause a severe and life-threatening allergic reaction (anaphylaxis). Omalizumab is approved for patients who have moderate-to-severe asthma related to allergies and whose symptoms are not controlled by inhaled corticosteroids. It is given by injection in a doctor’s office every 2 - 4 weeks.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Risk Factors
- Causes
- Diagnosis
- Other Disorders Associated ...
- Complications
- Treatment
- Medications
- Behavioral Management
- Other Treatments
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the Food and Drug Administration (FDA) approved lisdexamfetamine (Vysvanse), a new stimulant drug for the treatment of attention-deficit/hyperactivity disorder (ADHD). The active ingredient in lisdexamfetamine is similar to dextroamphetamine, the drug used in Dexedrine and Adderall.
Drug Warning
In 2007, the FDA instructed the manufacturers of all ADHD drugs to include drug warning labels describing the risks for heart and psychiatric side effects.
- 0 Comments
Oct 08, 2008 -
In This Report
- Highlights
- Introduction
- Causes
- Outlook and Effects
- Diagnosis
- Treatment
- Treatment After The First S...
- Medications
- Surgery
- Lifestyle Changes
- Resources
- References
HEALTH GUIDE REFERENCE FROM A.D.A.M
Highlights
Drug Approval
In 2007, the Food and Drug Administration (FDA) approved levetiracetam (Keppra) for treatment of primary generalized tonic-clonic seizures in adults, and children ages 6 years and older, who have idiopathic generalized epilepsy. Levetiracetam was previously approved for partial-onset seizures and myoclonic seizures.
Carbamazepine and Genetic Testing
In 2007, the FDA recommended that patients of Asian ancestry get a genetic test prior to taking carbamazepine (Tegetrol, Equetro, Carbatrol).
- 0 Comments
Cheap Monday
Masini Gioielli
DKNY